Ken Griffin Arcellx, Inc. Transaction History
Citadel Advisors LLC
- $483 Billion
- Q2 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Arcellx, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 20,900 shares of ACLX stock, worth $1.58 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
20,900
Previous 13,600
53.68%
Holding current value
$1.58 Million
Previous $945,000
22.01%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding ACLX
# of Institutions
174Shares Held
45.6MCall Options Held
53.6KPut Options Held
53.7K-
Perceptive Advisors LLC New York, NY3.89MShares$295 Million6.21% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY3.85MShares$291 Million8.59% of portfolio
-
Nea Management Company, LLC Timonium, MD3.75MShares$284 Million19.51% of portfolio
-
Black Rock Inc. New York, NY3.52MShares$266 Million0.0% of portfolio
-
Sr One Capital Management, LP2.35MShares$178 Million56.87% of portfolio
About Arcellx, Inc.
- Ticker ACLX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,819,200
- Market Cap $3.32B
- Description
- Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...